缺少XI因子:与年龄相关的表型考虑和临床方法对出血风险评估
Assaf Arie Barg1, Tami Livnat1, Gili Kenet1
1National Hemophilia Center, Coagulation Unit and Amalia Biron Research Institution of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel; and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
作为一种罕见的出血障碍,XI因子 (FXI) 缺乏症在所有年龄段都存在诊断和管理方面的挑战. 目前的测定难以预测出血风险,需要改进诊断方法和治疗方法.
科学领域:
- 血液学 血液学 血液学
- 罕见的出血疾病 罕见的出血疾病
- 凝血因子缺陷 凝血因子缺陷
背景情况:
- 十一因子 (FXI) 缺乏症是一种罕见的出血障碍,具有可变的临床表现和不可预测的出血倾向.
- 在FXI缺乏症下,出血风险评估因与血水平或基因型的不良相关性而复杂化.
- 年龄特定的考虑因素,包括新生儿,生育年龄的女性和老年人,带来了独特的管理挑战.
结论:
- 提出了一种精细的诊断方法,以改善FXI缺乏症的治疗策略和决策.
- 目前的治疗选择包括抗纤维解药,替代产品和复合激活FVII.
- 正在探索有前途的非替代疗法,以解决与FXI缺乏相关的出血并发症.
更多相关视频
13:08Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
相关概念视频
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Clot Retraction and Fibrinolysis
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
